April 13th 2022
Results of the phase 2 AURELIO-03 trial show SOT101 plus PD-1 inhibition induced responses in patients with advanced solid tumors.
Phase II Study of Pembrolizumab Finds Activity in Brain Metastases from NSCLCApril 26th 2020
The study found that pembrolizumab has activity in brain metastases from non-small cell lung cancer that is similar to its systemic activity and can result in prolonged survival in a subset of patients.
Researchers Develop Long Noncoding RNA-Based Immune Classes and Scores for ImmunotherapyApril 20th 2020
A recent study determined 4 distinct long noncoding RNA-based immune classes for patients with cancer and provided scores for integration into multiomic panels for precision immunotherapy.
Economic Evaluation of CAR T-Cell Therapies by Site Care for Large B-Cell LymphomasApril 16th 2020
Researchers found that the potential availability of CAR T-cell therapies for large B-cell lymphomas with lower adverse event rates that are suitable for outpatient administration may reduce the total costs of care.
Immunotherapy Among Patients with Melanoma and the Checkpoint Inhibitor EraMarch 21st 2020
Researchers analyzed a patient population with stage IV melanoma and found no difference in the rate of surgical resection with the use of immunotherapy between the checkpoint inhibitor era and pre-checkpoint inhibitor era.
Blood Test Predicts Clinical Response to Immunotherapy in Metastatic NSCLCFebruary 28th 2020
Researchers suggested that patients with non-small cell lung cancer (NSCLC) who have higher measures of tumor mutations that appear in a blood test generally have a better clinical response to PD-1-based immunotherapy than those with a lower measure of mutations.
Pembrolizumab Doubles Pathologic Complete Response Rates When Added to Standard NACTFebruary 18th 2020
According to the researchers, these data suggest that checkpoint blockade in women with early-stage, high-risk, ERBB2-negative breast cancer is very likely to succeed in a phase III trial.
FDA Grants 2 Fast Track Designations for ALX148February 18th 2020
The FDA granted 2 Fast Track designations for ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma.
Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, LymphomaFebruary 8th 2020
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLCJanuary 15th 2020
The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.
Promising Responses from Dual-Targeting CAR T-Cell Therapy in Myeloma Support Further ExplorationDecember 7th 2019
Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.
FDA Grants Priority Review to Durvalumab for Extensive-Stage Small Cell Lung CancerDecember 2nd 2019
The FDA accepted a supplemental biologics license application and granted a priority review to durvalumab for the treatment of patients with previously untreated extensive-stage small cell lung cancer.
FDA Grants Priority Review to Pembrolizumab for Non-Muscle Invasive Bladder CancerDecember 2nd 2019
The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the treatment of patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer.
Proof-of-Concept Study of CAR-NK Cell Therapy with Engineered Persistence Shows PotentialNovember 27th 2019
Robert A. Brodsky, MD discussed the study of a first-of-kind multi-antigen targeted off-the-shelf chimeric antigen receptor- natural killer cell therapy with engineered persistence that will be presented at the ASH Annual Meeting & Exposition.
Domenico Mallardo, MD, on Anti-CTLA4 Agents in MelanomaNovember 14th 2019
Domenico Mallardo, MD, Istituto Nazionale Tumori "Fondazione Pascale" in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).